Rituximab: all 1,389 studies that test it

Page 1 of 14. Open to participants first (177), then studies with results posted, then the rest; newest registration first within each.

• Combination of Rituximab and Cyclosporine in the Treatment of Primary Membranous NephropathyRecruitingNCT07861204Phase 2/3
• Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLLNot yet recruitingNCT07831395Phase 2
• Rituximab vs Placebo for Maintenance in Systemic Sclerosis - Interstitial Lung DiseaseNot yet recruitingNCT07827742Phase 2
• Rituximab With Corticosteroids Versus Corticosteroids Plus Azathioprine for Moderate-to-Severe Pemphigus VulgarisNot yet recruitingNCT07769333Early Phase 1
• Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After First-Line ResponseNot yet recruitingNCT07760610Phase 4
• Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular LymphomaRecruitingNCT07731789Phase 2
• A Randomized Controlled Trial of Prophylactic Rituximab to Reduce Clinically Significant EBV DNAemia After Allogeneic Hematopoietic Stem Cell TransplantationNot yet recruitingNCT07703657Not applicable
• Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse EventsRecruitingNCT07694414Phase 1
• Prevention of Epstein-Barr Virus Reactivation With the ATG-based Haploidentical Protocol Combined With Rituximab in Children Undergoing Allogeneic Hematopoietic Stem Cell TransplantationRecruitingNCT07693881Not applicable
• Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell LymphomaNot yet recruitingNCT07677813Phase 2
• Rituximab Combining With Low-Dose Mycophenolate Mofetil on Proliferative Lupus Nephritis in ChildrenNot yet recruitingNCT07675291Not applicable
• Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary FibrosisNot yet recruitingNCT07674745Phase 2
• Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone LymphomaNot yet recruitingNCT07654465Phase 2
• Treatment Strategy for Patients With RA-ILDNot yet recruitingNCT07643038Phase 4
• Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemiaNot yet recruitingNCT07614282Phase 1
• Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS LymphomasNot yet recruitingNCT07608731Phase 1
• Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell LymphomaNot yet recruitingNCT07601607Phase 1/2
• Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone LymphomaRecruitingNCT07583810Phase 2
• Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT07578077Phase 1/2
• The HIt HArd and hiT Early in Multiple Sclerosis TrialRecruitingNCT07517185Phase 2
• Immunomodulatory Therapy to Restore Ovarian Function and Improve Fertility in Women With Autoimmune Premature Ovarian InsufficiencyRecruitingNCT07509840Phase 3
• Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin LymphomaNot yet recruitingNCT07477366Phase 2
• Comparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis.Not yet recruitingNCT07451847Phase 4
• Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZLRecruitingNCT07448324Phase 2
• Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular LymphomaRecruitingNCT07418190Phase 2
• Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCLNot yet recruitingNCT07415980Phase 1/2
• PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.RecruitingNCT07410520Phase 2
• CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCLRecruitingNCT07397832Phase 2
• Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCLNot yet recruitingNCT07389356Not applicable
• Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT07365306Phase 2
• A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSLRecruitingNCT07350850Phase 2
• A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic SclerosisNot yet recruitingNCT07335562Phase 3
• Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell LymphomaRecruitingNCT07285590Phase 2
• Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk DiseaseRecruitingNCT07272499Phase 2
• Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell LymphomaRecruitingNCT07270835Phase 4
• Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell LymphomaNot yet recruitingNCT07269639Phase 1/2
• Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 StudyRecruitingNCT07257055Phase 2
• Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCLRecruitingNCT07255963Phase 2
• A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)RecruitingNCT07231952Phase 2
• Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)RecruitingNCT07225439Phase 1
• Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/LymphomaRecruitingNCT07224100Phase 2
• SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin LymphomasRecruitingNCT07222631Phase 1/2
• Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune ThrombocytopeniaRecruitingNCT07206823Not applicable
• Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL TreatmentRecruitingNCT07199296Phase 2
• Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström MacroglobulinemiaNot yet recruitingNCT07169565Phase 1
• Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingNCT07138898Phase 2
• Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaRecruitingNCT07097363Phase 2
• The Holistic StudyNot yet recruitingNCT07051915Phase 3
• Immunotherapy of the Recent-onset Type 1 Diabetes in Adolescents With Repeated Courses of RituximabRecruitingNCT07041268Phase 2
• A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1Not yet recruitingNCT07034508Phase 2
• A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous NephropathyNot yet recruitingNCT07029139Phase 2
• Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn DiseaseNot yet recruitingNCT06986382Phase 1/2
• Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)RecruitingNCT06983821Phase 3
• Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)RecruitingNCT06977711Phase 1
• ZR-MTX for PIOL Phase II TrialRecruitingNCT06973811Phase 2
• Study of the Efficacy and Safety for Rituximab in Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)RecruitingNCT06952413Phase 2
• A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)RecruitingNCT06943872Phase 3
• Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's MacroglobulinemiaNot yet recruitingNCT06942507Not applicable
• Evaluation of 200 mg of Rituximab Every 6 Months as Maintenance Treatment of Rituximab-treated Patients With Rheumatoid ArthritisRecruitingNCT06906549Phase 4
• Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell LymphomaRecruitingNCT06846489Phase 2
• Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell LymphomaRecruitingNCT06839053Phase 2
• Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyRecruitingNCT06834373Phase 2
• HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZLRecruitingNCT06792825Phase 2
• Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)RecruitingNCT06788964Phase 2
• Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating PolyneuropathyRecruitingNCT06714838Phase 3
• Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 AntibodyRecruitingNCT06688331Phase 2
• NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus NephritisRecruitingNCT06676631Phase 1
• Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated VasculitisRecruitingNCT06611696Phase 4
• Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)RecruitingNCT06607549Phase 1
• The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple SclerosisRecruitingNCT06599307Phase 2
• R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell LymphomaRecruitingNCT06594640Phase 1/2
• Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.RecruitingNCT06581562Phase 1
• A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCLNot yet recruitingNCT06573645Phase 3
• Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell LymphomaRecruitingNCT06572618Phase 2
• Epco, Zanu, Ritux for R/R FL or MZLRecruitingNCT06563596Phase 2
• Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WMRecruitingNCT06561347Phase 2
• MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin LymphomaNot yet recruitingNCT06557330Phase 2
• A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingNCT06554600Phase 2
• A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System LymphomaRecruitingNCT06554561Phase 1/2
• Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic SclerosisRecruitingNCT06549231Phase 3
• Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCLRecruitingNCT06530511Phase 2
• The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell LymphomaRecruitingNCT06522555Phase 3
• Rituximab Plus Venetoclax in Front Line Marginal Zone LymphomaRecruitingNCT06510309Phase 2
• Bendamustine and Rituximab With or Without Orelabrutinib in MCL TreatmentRecruitingNCT06496308Phase 3
• Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular LymphomaRecruitingNCT06471738Phase 2
• MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell LymphomaRecruitingNCT06414148Phase 2
• Belimumab After Rituximab in Resistant Primary Juvenile SSRecruitingNCT06410833Phase 4
• Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)RecruitingNCT06390956Phase 2
• Rituximab and Zanubrutinib in Patients With Indolent B-cell LymphomasRecruitingNCT06350318Phase 2
• Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX)RecruitingNCT06341205Phase 3
• Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular LymphomaRecruitingNCT06337318Phase 3
• Ma-Spore ALL 2020 StudyRecruitingNCT06336395Phase 2
• Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) PatientsRecruitingNCT06263491Phase 2
• Rituximab for Serious Aplastic Anemia With Platelet Transfusion RefractorinessRecruitingNCT06254560Phase 2
• the Effects of Different Treatment Schemes on Cognitive Function of Patients With Idiopathic Membranous NephropathyRecruitingNCT06245707Not applicable
• CC-99282 + Rituximab Early Post CART for Non-Hodgkin's LymphomaRecruitingNCT06209619Phase 1
• BV-AVD-R Treatment Children Hodgkin's LymphomaEnrolling by invitationNCT06201507Phase 2
• RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT LymphomaRecruitingNCT06190301Not applicable
• Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL PatientsRecruitingNCT06176729Phase 2
• A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone LymphomaRecruitingNCT06149286Phase 3

← Rituximab overview